Robert Peter Kadlec - 30 Oct 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Director
Signature
/s/Christine Klaskin, as Attorney-in-Fact
Issuer symbol
INKT
Transactions as of
30 Oct 2024
Transactions value $
$8,969
Form type
4
Filing time
09 Dec 2024, 16:10:04 UTC
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INKT Common Stock Award $8.97K +12.3K $0.73 12.3K 01 Dec 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option Award $0 +41.7K $0.00 41.7K 30 Oct 2024 Common Stock 41.7K $0.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on October 30, 2024 and will vest in three equal annual installments on each of October 30, 2025, 2026 and 2027 (provided Dr. Kadlec maintains a service relationship with the company through each such vesting date).
F2 Dr. Kadlec was granted restricted stock unites ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.